LINK Medical

22 June 2023 07:30

LINK Medical contracted by Hemanext to run a study to assess the Hemanext ONE® Red Blood Cell (RBC) Processing and Storage System

Hemanext, inc. appoints LINK Medical Research to run a study to assess the Hemanext ONE® Red Blood Cell (RBC) Processing and Storage System. The study will include patients that receive transfusions of hypoxic RBC units processed with Hemanext ONE, with the purpose of evaluating the safety and efficacy of hypoxic red blood cells processed with the Hemanext ONE system.

LIPIGON chooses chosen LINK Medical, a Nordic contract research organization (CRO) for the planning and design of their clinical phase II study with Lipisense.

29 May 2023 07:00

LIPIGON CHOOSES LINK MEDICAL AS THEIR CRO

Lipigon Pharmaceuticals AB have chosen LINK Medical, a Nordic contract research organization (CRO) for the planning and design of their clinical phase II study with Lipisense. The study aims to study safety and treatment effects in patients with severely elevated levels of the blood fat triglyceride.

Märta Segerdahl, project leader and CMO at AlzeCure Pharma,  Sissel Lønning Andresen, CEO LINK Medical, Martin Jönsson AlzeCure CEO

28 May 2023 15:23

Positive Results for AlzeCure’s Phase IIa clinical study in neuropathic pain with the non-opioid ACD440

LINK Medical, and AlzeCure® Pharma AB (publ) (FN STO: ALZCUR) announce the positive data results from the Phase IIa clinical study with the non-opioid drug candidate ACD440, which is developed against peripheral neuropathic pain

23 March 2023 13:11

Pharm Assist is now part of LINK Medical, making the Regulatory team one of the largest and unique in Northern Europe

1 February 2023 09:00

The patient recruitment milestone has been reached for AlzeCure's Phase II clinical trial in neuropathic pain with non-opioid ACD440

LINK Medical, the Northern European clinical research organization (CRO), and AlzeCureÒ Pharma AB (publ) (FN STO: ALZCUR), announced today that the last patient has been enrolled in the phase II clinical trial for neuropathic pain treated with the non-opioid ACD440.

Categories: clinical studies

LINK Medical contracted by Hemanext to run a study to assess the Hemanext ONE® Red Blood Cell (RBC) Processing and Storage System

LIPIGON CHOOSES LINK MEDICAL AS THEIR CRO

Positive Results for AlzeCure’s Phase IIa clinical study in neuropathic pain with the non-opioid ACD440

Pharm Assist is now part of LINK Medical, making the Regulatory team one of the largest and unique in Northern Europe

The patient recruitment milestone has been reached for AlzeCure's Phase II clinical trial in neuropathic pain with non-opioid ACD440

Your trusted CRO partner